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costs are presented. RESULTS: First year costs of non-fatal
myocardial infarction varied between 15,592€ in France and
4,089€ in Spain. In subsequent years of treatment, this range was
1226€ (France) to 738€ (Spain). Angina costs were similar across
all four countries: 2613€ in France; 3342€ in Germany; 2297€
in Italy; and 2207€ in Spain. Event costs of non-fatal stroke were
higher in Germany (19,399€) than in other countries (France
11,754€; Italy 6,583€; Spain 4,638€). Event costs of end-stage
renal disease varied depending on the type of dialysis in 
France (24,608–56,487€), Germany (46,296–68,175€), Italy
(43,075–56,717€) and Spain (28,370–32,706€). Lower extrem-
ity amputation costs were 31,998€ (France); 22,096€ (Germany);
10,177€ (Italy); and 14,787€ (Spain). CONCLUSIONS: Overall,
our search showed costs are well documented in France and
Germany, but revealed a paucity of data for Spain and Italy.
Spanish costs, collected by contacting local experts and from
government reports, generally appeared to be lower for treating
cardiovascular complications than in other countries. Italian
costs reported in the literature were primarily hospitalization
costs derived from diagnosis-related groups, and therefore likely
to overestimate the cost of speciﬁc complications. Additional
research is required to document complication costs in Spain and
Italy. These data are essential for creating models of diabetes able
to accurately simulate the cumulative costs associated with the
progression of this disease and its complications.
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OBJECTIVES: In a recent randomized, controlled clinical study
in patients with type-1 diabetes, use of insulin detemir (IDet)
versus neutral protamine Hagedorn (NPH) insulin in a basal
(twice daily)/bolus regimen with insulin aspart (IAsp) as bolus,
demonstrated that IDet/IAsp was associated with a relative risk
reduction of 21% for hypoglycaemic events (p < 0.05), a reduc-
tion of 1.01kg in body weight (p < 0.05) and decreased systolic
blood pressure (SBP) (3mmHg, p < 0.05) versus NPH/IAsp over
six months of treatment. No signiﬁcant difference in HbA1c was
noted. The aim of this analysis was to assess the impact of these
changes over long-term treatment with IDet/IAsp versus
NPH/IAsp. METHODS: The CORE Diabetes Model, a peer-
reviewed, validated computer simulation model, was used to
project these short-term ﬁndings to evaluate long-term clinical
and cost outcomes. Transition probabilities and risk adjustments
were derived from published studies. Baseline cohort character-
istics were taken from the clinical trial. Total direct costs 
(complications + treatment costs) were derived from published
sources and projected over patients’ lifetimes from a Dutch
National Health care perspective. Costs and clinical beneﬁts
were discounted at 3.5% per annum. RESULTS: Decreased inci-
dence of hypoglycemic events, improved BMI and SBP associ-
ated with IDet/IAsp treatment led to fewer diabetes-related
complications, increased life expectancy (0.17 years) and
improved quality-adjusted life expectancy (0.11 QALYs) com-
pared to NPH/IAsp. Mean total lifetime costs were 626€/patient
higher in the IDet/IAsp treatment arm than in the NPH/IAsp
group, leading to incremental cost-effectiveness ratios of 3682€
per LYG and 5691€ per QALY gained. CONCLUSIONS: Short-
term clinical improvements associated with IDet/IAsp were pro-
jected to lead to a lower incidence of complications, improved
life expectancy and quality-adjusted life expectancy over patient
lifetimes. Reductions in the cost of complication partially offset
the costs of IDet/IAsp treatment, leading to incremental cost-
effectiveness ratios within the range considered to represent
excellent value for money.
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DIABETIC RETINOPATHY MODELING:A COST-
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OBJECTIVES: To assess the cost-effectiveness of various screen-
ing intervals using indirect ophthalmoscopy performed by oph-
thalmologists for detecting diabetic retinopathy among type-2
diabetic patients from hospital and societal perspectives in 
Thailand. METHODS: A Markov model of diabetes retinopa-
thy was constructed based on Eastman model. A cohort of
10,000 newly diagnosed, type-2 diabetic patients age 40 years
was simulated until the age of 75 years or death. Transition prob-
abilities were obtained from literature review, while unit costs
and utilization patterns in Thai population were derived from a
hospital and expert opinions. Costs of screening and treatment
were calculated using a microcosting technique. Incremental
cost-effectiveness analyses were performed based on a cohort
simulation and presented as incremental Baht per blindness 
prevented. A series of sensitivity analyses were performed.
RESULTS: In base-case analysis using a hospital perspective, an
incremental cost-effectiveness ratio (ICER) of screening every
four-years compared to no screening was 85,976 Baht per blind-
ness prevented. Comparing to the next preceding screening fre-
quency, the ICER of screening frequency every four-years, every
three-years, and two-years was 62,806, 70,554, 95,865 Baht 
per blindness prevented, respectively. When varying the cost of
screening and laser treatment, probability of seeking medical
treatment among unscreened, probability of being treated with
vitrectomy, and annual mortality rate, the results remained
similar to the base-case analysis. However, when we performed
analysis using a societal perspective, all screening patterns
resulted in cost-saving. CONCLUSIONS: Our ﬁndings indicated
that an incremental cost incurred from increasing frequency in
all screening intervals was less than 100,000 Baht or US$2,500
per one blindness prevented. Annual diabetic retinopathy screen-
ing seems to be a cost-effectiveness intervention, especially from
a societal perspective. Our ﬁndings can be a very useful infor-
mation to aid health care policy decision makers during their
decision making process.
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OBJECTIVE: To examine how the type-2 diabetes-related direct
medical costs are associated with an individual’s level of glycemic
control. METHODS: The analysis was performed on data from
a large health plan administrative database. Individuals were
deﬁned an index date between October 1, 1999 and April 30,
2001, based upon ﬁrst diagnosis of diabetes or use of antidia-
betic agent and were retrospectively examined in the 12 months
pre- and 24–43 months post-index date (N = 10,780). Differ-
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ences in costs between HbA1c groups were analyzed using a gen-
eralized linear model (GLM), controlling for demographics,
patient severity, as well as comorbidities and complications.
RESULTS: In total, 79% of individuals in the analysis obtained
good HbA1c (HbA1c of less than or equal to seven) control at
some time during the post-period although only 59% of these
individuals maintained this level of glycemic control for the dura-
tion of follow-up. Individuals in the fair (HbA1c greater than
seven to less than or equal to nine) or poor (HbA1c greater 
than nine) groups had signiﬁcantly higher diabetes related 
total medical costs compared to individuals with good glycemic
control ($1641 v. $1372 per member per year [PMPY]; p < 0.05;
$1705 v. $1372 PMPY; p < 0.05, respectively). CONCLU-
SIONS: Although initially successful at obtaining good glycemic
control, a large percentage of individuals were unable to main-
tain such control. This is coupled with a ﬁnding of higher dia-
betes-related medical costs for individuals at sub-optimal levels
of control. These results suggest that novel therapies which
improve the capability of individuals to achieve and maintain
glycemic control may have positive ﬁnancial as well as health
implications.
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OBJECTIVES: To evaluate the effect of symptoms of diabetic
peripheral neuropathy (SDPN), diabetic retinopathy (DR) and
co-morbid SDPN & DR (COMORB) among US adults ≥40 years
old with diagnosed diabetes on several burden of illness (BOI)
measures, including indirect costs and health care utilization,
using the combined 1999–2000 and 2001–2002 National Health
and Nutrition Examination Surveys (NHANES). METHODS:
Included in the analysis were 850 NHANES respondents ≥40
years old classiﬁed as having diagnosed diabetes. Logistic 
regression models were used to assess the effect of SDPN, DR
and COMORB on BOI. Model covariates included age, gender,
race, education, insurance status, current smoking status, cur-
rently asthmatic, and history of cardiovascular disease, cancer,
arthritis, COPD, hypertension and stroke. The conditions of
interest were assessed based upon respondent self-report.
RESULTS: Using the combined 1999–2000 and 2001–2002
NHANES, it was estimated that, among US adults ≥40 years old
with diagnosed diabetes, those with SDPN (OR = 2.27; 95% CI
= 1.34, 3.85), DR (1.67; 1.08, 2.59) and COMORB (2.88; 1.28,
6.48) were each more likely to have four or more health care
visits in the past year than those without the corresponding 
condition. Those with DR (1.81; 1.31, 2.50) and COMORB
(2.07; 1.13, 3.77) were both more likely to have had at least 
one overnight hospital stay in the past year. Finally, those of
working age (40–65) with SDPN (3.39; 1.66, 6.89), DR (3.08;
1.55, 6.11) and COMORB (4.51; 2.27, 8.96) were each more
likely to be unable to work due to physical limitations. CON-
CLUSION: Among US adults ≥40 years old with diagnosed dia-
betes, SDPN, DR, and COMORB all appear to signiﬁcantly
increased BOI. Future therapies that offer relief of both of these
conditions may have signiﬁcant beneﬁts on indirect costs (such
as lost work time) and direct measures of health care resource
utilization.
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OBJECTIVE: To carry out economic evaluation of drug therapy
among diabetic patients. METHODS: The methodology was
Cost of Illness Analysis. Out–Patients were considered. Drug
review was carried out retrospectively for randomly sampled 37
case notes over one-year period. Demographic data were col-
lected and number of hospital visits, fasting blood sugar and
blood pressure at each visit, drugs prescribed at each visit. Cost
components were the direct costs. These include the total cost of
drugs over one-year period, personnel cost, diagnostic costs, and
transport cost. Hospital cost of the drugs were used, cost per
deﬁned daily dose of each drugs were calculated as well as the
total drug cost, taken the duration of therapy into consideration.
Stop-watch-time studies and monthly earnings were used in the
calculation of personnel cost. Since the study covers one year
period (July, 2003–August, 2004) neither discounting nor inﬂa-
tion were considered in the analysis. RESULTS: Most of the
patients were Type-II Diabetes Mellitus (n = 33; 89.2%) while
Type-I (insulin required) were four (10.8%). In total, 83.8%
were hypertensive. Total costs of drugs = N1,219,932.70 (US
$8,713.81), Anti-diabetic drugs = N689,231.50 (US $4,923.82)
(56.5%), Anti-hypertensive drugs = N530,701.20 (US $3,790)
(44.5%), Transport = N30,696.70, Diagnostic = N56,400, Per-
sonnel = N53,340.40. Total Cost of Illness for one year for 37
patients = N1,360,369.80 (US $9,716.93). Total cost of treating
1000 patients = N1,360,369800.00 (US $9,716,930.00) aside
indirect cost among others per year. Average cost per patient =
N36,766.75 (US $262.62) (84.7% of N43,400.00 (US $310.0)
per capital income in Nigeria). Range; N2,618.44 (US $18.70)
and N268,572.81 (US $1918.38). N = Naira. CONCLUSION:
Spending an average of 84.7% of per capital income to treat an
illness annually is highly unfortunate as this further worsens the
quality of life of such patients. This call for good understanding
of the disease condition by the society to minimize the incidence
while ensuring compliance and also for improved policy by 
government.
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OBJECTIVES: The aim of this study was to collect cost data on
the complications associated with diabetes mellitus in Canada
and Australia for use in a published, validated computer simu-
lation model of the disease. METHODS: A search for costs data
was performed in PubMed to identify peer-reviewed cost data in
Canada and Australia published in the last ten years. Costs not
identiﬁed in the literature were gathered from published gov-
ernment reports (sources included reports from the Provincial
Ministry of Health in Ontario and Newfoundland). All costs
were inﬂated to 2004 values. Major complication costs are pre-
sented. RESULTS: The costs of diabetes complications are well
documented in Canada, but there is a paucity of published cost
data for Australia. No Australian cost data were identiﬁed, and
a specialist research program has been initiated to generate this
information. In Canada, the event costs for non-fatal myocardial
